Immunocore (IMCR) director Kristine Peterson receives 27,492 stock options at $28.52

Rhea-AI Filing Summary

Immunocore Holdings plc reported that director Kristine Peterson received a stock option grant covering 27,492 ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036. The award vests at the earlier of May 27, 2027 or the day immediately prior to the company’s next annual general meeting, contingent on her continued service. This is a compensation-related award rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peterson Kristine

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	27,492	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 27,492 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 27,492 options Exercise price: $28.52 per share Total options after grant: 27,492 options +2 more

5 metrics

Options granted 27,492 options Share Option (Right to Buy) covering ordinary shares

Exercise price $28.52 per share Conversion or exercise price of option grant

Total options after grant 27,492 options Total derivative securities following transaction

Expiration date May 26, 2036 Option award expiration

Vesting date Earlier of May 27, 2027 or pre-next AGM Vesting contingent on continuous service

Key Terms

Share Option (Right to Buy), Grant, award, or other acquisition, annual general meeting

3 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)" for ordinary shares"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

annual general meeting financial

"earlier of May 27, 2027 and the day immediately prior to the date of the Issuer's next annual general meeting"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Kristine

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON OXFORDSHIRE OX14 4RY

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$28.52	05/27/2026		A		27,492		(1)	05/26/2036	Ordinary Shares	27,492	$0	27,492	D

Explanation of Responses:

1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunocore (IMCR) director Kristine Peterson report on this Form 4?

Kristine Peterson reported receiving a grant of options for 27,492 Immunocore ordinary shares. These stock options are a compensation-related award, not an open-market trade, and give her the right to buy shares at a fixed exercise price in the future.

How many Immunocore (IMCR) options were granted to Kristine Peterson and at what price?

She was granted options over 27,492 ordinary shares at an exercise price of $28.52 per share. This means she can purchase shares at $28.52 regardless of future market price, subject to vesting and expiration terms disclosed in the filing.

When do Kristine Peterson’s Immunocore (IMCR) options vest according to the Form 4?

The options vest at the earlier of May 27, 2027, or the day immediately before Immunocore’s next annual general meeting. Vesting is conditional on her remaining in continuous service with the company through that vesting date, as described in the footnote.

What is the expiration date of Kristine Peterson’s Immunocore (IMCR) stock options?

The options expire on May 26, 2036, if not exercised earlier. After that date, any unexercised portion of the 27,492-share award will lapse, and she will no longer have the right to purchase Immunocore ordinary shares under this grant.

Does this Immunocore (IMCR) Form 4 show Kristine Peterson buying or selling shares on the market?

No, it shows a grant of stock options as compensation, coded as an acquisition. There were no open-market purchases or sales reported, only the issuance of new options giving future rights to acquire ordinary shares at a set price.